XBiotech Advances Phase 1/2 Clinical Study of Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus Aureus

September 01, 2015 at 07:01 AM EDT

XBiotech (NASDAQ: XBIT), the world's leading developer of next-generation True Human™ therapeutic antibodies, announced today the ...